Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cup.12662 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pilot Study: Human Adipose Tissue Allograft for Fat Pad Defects in Patients With Preulcerative Lesions.
Plast Reconstr Surg Glob Open
December 2024
Britecyte, Inc., Frederick, MD.
Background: Loss or displacement of a fat pad on the foot increases plantar pressure, leading to pain and plantar ulcers. These ulcers, especially in patients with diabetic neuropathy, have high recurrence rates, often resulting in amputations. Standard of care focuses on reducing plantar pressure with shoe padding or orthotic devices, leaving the restoration of the fat pad as an unmet medical need.
View Article and Find Full Text PDFInvestigation of Effectiveness of Nowarta110 Against Murine Malignant Melanoma in an Implanted Animal Model.
Anticancer Res
December 2024
USC-Fobic Therapeutic Innovation Initiative, Department of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, U.S.A.
Article Synopsis
- Melanoma is a serious disease that requires new treatment options, and Nowata110 has shown promising results in both treating plantar warts and showing anti-cancer effects in previous studies using specific cervical cancer models.
- The study used male and female mice, both immunocompetent and immunodeficient, to test the effectiveness of Nowata110 on implanted murine melanoma cells, with treatment given either intravenously or directly into the tumor.
- Results indicated that Nowata110 reduced tumor growth significantly in both types of mice, with the most notable efficacy seen in immunocompetent mice, leading to the suggestion that further clinical studies should be conducted for human melanoma.
"The Ultrathin Parascapular Flap: Proof of Concept and Use in Plantar Foot Reconstruction".
Plast Reconstr Surg
November 2024
Department of Plastic Surgery, Asan Medical Center, University of Ulsan, Seoul, South Korea.
Optimal reconstruction of weight-bearing plantar foot defects is challenging due to the need for relatively thin coverage with simultaneous durability. The medial plantar flap provides an excellent tissue match but is not always available or appropriate (Figure 1, 2). Microsurgical free flap reconstruction provides many options for coverage.
View Article and Find Full Text PDFInvestigation of the Efficacy of Nowarta110 in the Treatment of HPV-16 and HPV-18 Oncogenically-transformed Human Cells and Cancer-implanted Animal Models.
Anticancer Res
November 2024
USC-Fobic Therapeutic Innovation Initiative Department of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA, U.S.A.
Background/aim: Cervical cancer is the third leading cause of cancer-related death in women worldwide. Nearly all cases of cervical cancer are due to infection with human papillomavirus (HPV). Nowarta110 has shown breakthrough therapeutic efficacy in phase II clinical study against plantar warts, with no reported side effects.
View Article and Find Full Text PDFA disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
Ther Adv Drug Saf
October 2024
Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 321 Zhongshan Road, Nanjing 210008, China.
Objectives: This pharmacovigilance analysis was conducted to assess the safety signals of FMS-related tyrosine kinase 3 (FLT3) inhibitors in a real-world setting using the United States Food and Drug Administration Adverse Event Reporting System (FAERS).
Design: We analyzed adverse event (AE) reports related to FLT3 inhibitors submitted to the FAERS database from the first quarter of 2015 to the fourth quarter of 2022. Disproportionality analysis was used to identify AEs of FLT3 inhibitors in the FAERS database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!